These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29423505)

  • 1. Laboratory Eligibility Criteria as Potential Barriers to Participation by Black Men in Prostate Cancer Clinical Trials.
    Vastola ME; Yang DD; Muralidhar V; Mahal BA; Lathan CS; McGregor BA; Nguyen PL
    JAMA Oncol; 2018 Mar; 4(3):413-414. PubMed ID: 29423505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil count in African Americans: lowering the target cutoff to initiate or resume chemotherapy?
    Hsieh MM; Tisdale JF; Rodgers GP; Young NS; Trimble EL; Little RF
    J Clin Oncol; 2010 Apr; 28(10):1633-7. PubMed ID: 20194862
    [No Abstract]   [Full Text] [Related]  

  • 3. Pancreatic Cancer Clinical Treatment Trials Accrual: A Closer Look at Participation Rates.
    Guerra CE; Kelly S; Redlinger C; Hernández P; Glanz K
    Am J Clin Oncol; 2021 Jun; 44(6):227-231. PubMed ID: 33710138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial Disparities in Access to Prostate Cancer Clinical Trials: A County-Level Analysis.
    Wang WJ; Ramsey SD; Bennette CS; Bansal A
    JNCI Cancer Spectr; 2022 Feb; 6(1):. PubMed ID: 35047752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of overall survival in a large multiethnic cohort reveals absolute neutrophil count of 1,100 as a novel prognostic cutoff in African Americans.
    Mantzaris I; Yu Y; Msaouel P; Lam AP; Janakiram M; Friedman EW; Steidl U; Verma AK
    Oncotarget; 2016 Oct; 7(42):67948-67955. PubMed ID: 27144332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers and strategies for sustained participation of African-American men in cohort studies.
    Hughes GD; Sellers DB; Fraser LB; Knight B; Areghan GA
    Ethn Dis; 2003; 13(4):534-6. PubMed ID: 14632274
    [No Abstract]   [Full Text] [Related]  

  • 7. Challenging assumptions about minority participation in US clinical research.
    Fisher JA; Kalbaugh CA
    Am J Public Health; 2011 Dec; 101(12):2217-22. PubMed ID: 22021285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does absolute neutrophil count predict high tumor grade in African-American men with prostate cancer?
    Sadeghi N; Badalato GM; Hruby G; Grann V; McKiernan JM
    Prostate; 2012 Mar; 72(4):386-91. PubMed ID: 21681777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Danger of Applying the ProtecT Trial to Minority Populations.
    McClelland S; Mitin T
    JAMA Oncol; 2018 Mar; 4(3):291. PubMed ID: 29450467
    [No Abstract]   [Full Text] [Related]  

  • 10. Examining Differences in Opportunity and Eligibility for Cancer Clinical Trial Participation Based on Sociodemographic and Disease Characteristics.
    Rearden J; Hanlon AL; Ulrich C; Brooks-Carthon M; Sommers M
    Oncol Nurs Forum; 2016 Jan; 43(1):57-66. PubMed ID: 26679445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. African American Participation in Oncology Clinical Trials--Focus on Prostate Cancer: Implications, Barriers, and Potential Solutions.
    Ahaghotu C; Tyler R; Sartor O
    Clin Genitourin Cancer; 2016 Apr; 14(2):105-16. PubMed ID: 26786562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consecutive screening and enrollment on clinical trials.
    Bjørn M; Brendstrup C; Karlsen S; Carlsen JE
    J Card Fail; 1999 Sep; 5(3):283-4. PubMed ID: 10496202
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of eligibility criteria from ClinicalTrials.gov.
    Doods J; Dugas M; Fritz F
    Stud Health Technol Inform; 2014; 205():853-7. PubMed ID: 25160308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Social factors affecting interest in participating in a prostate cancer chemoprevention trial.
    Lee MM; Chamberlain RM; Catchatourian R; Hiang J; Kopnick M; Ray P; Vijayakumar S
    J Cancer Educ; 1999; 14(2):88-92. PubMed ID: 10397483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inclusion of black Americans in oncology clinical trials: the Louisiana State University Medical Center experience.
    Holcombe RF; Jacobson J; Li A; Moinpour CM
    Am J Clin Oncol; 1999 Feb; 22(1):18-21. PubMed ID: 10025373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recruitment strategies and comparison of prostate cancer-specific clinical data on African-American and Caucasian males with and without family history.
    Mandal DM; Sartor O; Halton SL; Mercante DE; Bailey-Wilson JE; Rayford W
    Prostate Cancer Prostatic Dis; 2008; 11(3):274-9. PubMed ID: 18268528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Processes in Increasing Participation of African American Women in Cancer Prevention Trials: Development and Pretesting of an Audio-Card.
    Kenerson D; Fadeyi S; Liu J; Weriwoh M; Beard K; Hargreaves MK
    J Health Commun; 2017 Dec; 22(12):933-941. PubMed ID: 29131708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation.
    Unger JM; Vaidya R; Hershman DL; Minasian LM; Fleury ME
    J Natl Cancer Inst; 2019 Mar; 111(3):245-255. PubMed ID: 30856272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recruiting black men to a clinical trial to evaluate prostate cancer screening--Detroit, Michigan, 1998.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1998 Aug; 47(33):694-6. PubMed ID: 9733417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for patient recruitment into clinical trials.
    Yusuf S
    J Card Fail; 1998 Sep; 4(3):235-6. PubMed ID: 9754595
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.